Clinical Trial

WATCHMAN FLX Pro European Registry

Recruiting
View on ClinicalTrials.gov →
Summary
The WATCHMAN FLX Pro European registry is intended to gather real world clinical data for patients undergoing left atrial appendage closure (LAAC) with the WATCHMAN FLX™ Pro device. In a subregistry with approximately 300 patients, it is intended to use the VersaCross Connect™ LAAC Access Solution.
Protocol Amendment History 3 changes
notable Trial sites expanded: 14 -> 18 locations 2026-08-05
critical Phase changed: not applicable -> not specified 2026-05-27
notable Trial sites expanded: 7 -> 11 locations 2026-05-09
Trial Details
NCT Number NCT07262255
Lead Sponsor Boston Scientific Corporation
Conditions Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure
Enrollment 1,000 participants
Start Date 2025-12-17
Primary Completion 2027-08 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-13